Johnson & Johnson expects $2.5 billion in global sales from Covid vaccine this year

Earnings

In this article

In this photo illustration a Johnson & Johnson logo is seen in front of a medical syringe and a vial with coronavirus vaccine.
Pavlo Gonchar | SOPA Images | LightRocket | Getty Images

Johnson & Johnson said Wednesday it expects to sell $2.5 billion of its Covid-19 vaccine, even as concerns mount over the shot’s effectiveness against the delta variant.

In releasing its second-quarter financial results, the company also reported earnings and revenue that beat Wall Street’s expectations.

Here’s how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:

  • Adjusted EPS: $2.48 per share vs $2.27 expected.
  • Revenue: $23.31 billion vs $22.21 billion expected.

The company’s share price was up nearly 1% in premarket trading following the report.

This is a developing story. Please check back for updates.

Products You May Like

Articles You May Like

Mortgage Regulators To Eliminate Controversial Refinancing Fee
It’s been 12 years since the last federal minimum wage increase. Where efforts to raise the pay rate stand
How criminals siphoned off unemployment payments directly from recipients’ accounts
Here’s how Black Americans can begin building wealth right now
Stocks making the biggest moves midday: State Street, Norwegian Cruise Line, iHeartMedia and more